Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era.
Antonio GutierrezLeyre BentoAntonio Diaz-LopezGilberto BarrancoMarta Garcia-RecioArmando Lopez-GuillermoIvan DlouhyJordina RoviraMario RodriguezJose María Sanchez PinaMonica BaileAlejandro MartínSilvana NovelliJuan-Manuel SanchoOlga GarcíaAntonio Salar-SilvestreMariana Bastos-OreiroMª José Rodriguez-SalazarRuben FernandezFatima de la CruzJose Antonio QueizanSonia González de VillambrosiaRaul CordobaAndres LópezHugo LuzardoDaniel GarcíaJordi Sastre-SerraJuan Fernando GarciaCarlos MontalbanFernando CabanillasJose RodríguezPublished in: European journal of haematology (2020)
(a) All variables of the original TS retain an independent prognostic role, and R-TS remains predictive in the rituximab era; (b) R-TS and additional categorization of LDH, B2M, and AA stage (enhanced TS) increased the ability to identify HR subsets.